Transgene Biotek Stock Price Analysis and Quick Research Report. Is Transgene Biotek an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Transgene Biotek. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Transgene Biotek has a PE ratio of -22.8587962962963 which is low and comparatively undervalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Transgene Biotek has ROA of -2.0195% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Transgene Biotek has a Current ratio of 0.0998.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Transgene Biotek has a ROE of 0%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Transgene Biotek has a Debt to Equity ratio of -2.0377 which means that the company has low proportion of debt in its capital.

• Sales growth: Transgene Biotek has reported revenue growth of 326.3158% which is fair in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Transgene Biotek for the current financial year is -258.109833971903%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Transgene Biotek is Rs 0 and the yield is 0%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Transgene Biotek is Rs -0.1728. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Transgene Biotek in Ticker for free. Also, one can get the intrinsic value of Transgene Biotek by using Valuation Calculators, which are available with a Finology ONE subscription. 

Transgene Biotek FAQs

Q1. What is Transgene Biotek share price today?
Ans: The current share price of Transgene Biotek is Rs 3.95.

Q2. What is the market capitalisation of Transgene Biotek?
Ans: Transgene Biotek has a market capitalisation of Rs 29.92915 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Transgene Biotek?
Ans: The PE ratio of Transgene Biotek is -22.8587962962963 and the P/B ratio of Transgene Biotek is -3.75047474363844, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Transgene Biotek share?
Ans: The 52-week high share price of Transgene Biotek is Rs 8.4, and the 52-week low share price of Transgene Biotek is Rs 3.22.

Q5. Does Transgene Biotek pay dividends?
Ans: Currently, Transgene Biotek does not pay dividends. Dividend yield of Transgene Biotek is around 0%.

Q6. What are the face value and book value of Transgene Biotek shares?
Ans: The face value of Transgene Biotek shares is Rs 10, while the book value per share of Transgene Biotek is around Rs -1.0532. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Transgene Biotek?
Ans: Transgene Biotek has a total debt of Rs 14.001 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Transgene Biotek?
Ans: The ROE of Transgene Biotek is 0% and ROCE of Transgene Biotek is -7.3466%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Transgene Biotek a good buy for the long term?
Ans: The Transgene Biotek long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Transgene Biotek undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Transgene Biotek appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Transgene Biotek’s financials?
Ans: You can review Transgene Biotek’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.